Assessment of Objective Response with 18F-FDG PET/CT in Vertebral Giant Cell Tumor Treated with RANKL Monoclonal Antibody
10.3969/j.issn.1005-5185.2025.03.016
- VernacularTitle:18F-FDG PET/CT评估脊柱骨巨细胞瘤RANKL单抗疗效的价值
- Author:
Le SONG
1
;
Hui LI
1
;
Annan ZHANG
1
;
Weifang ZHANG
1
Author Information
1. 北京大学第三医院核医学科,北京 100191
- Publication Type:Journal Article
- Keywords:
Giant cell tumor of bone;
Positron emission tomography computed tomography;
Fluorodeoxyglucose F18;
Antibodies,monoclonal;
Response evaluation
- From:
Chinese Journal of Medical Imaging
2025;33(3):315-319
- CountryChina
- Language:Chinese
-
Abstract:
Purpose To explore the value of 18F-FDG PET/CT for assessing the therapeutic effect of RANKL monoclonal antibody for vertebral giant cell tumors.Materials and Methods PET/CT data of 11 patients with vertebral giant cell tumors treated with RANKL monoclonal antibody in Peking University Third Hospital from October 2020 to September 2021 were retrospectively collected.Imaging characteristics such as the number,location and type of bone destruction were analyzed,the maximum standardized uptake value(SUVmax)and the longest diameter of the lesions were measured.The objective tumor response was evaluated based on the modified European organization for research and treatment of cancer(EORTC)criteria,response evaluation criteria in solid tumors(RECIST)1.1 and inverse Choi density/size(ICDS)criteria.Results The skeletal lesions of 11 patients were all single,with lytic destruction and incomplete bone cortex,and marginal bone sclerosis was observed after treatment.The lesions had a baseline SUVmax of 12.12±3.64 and a post-treatment SUVmax of 4.39±2.10,with a%ΔSUVmax ranging from 31.81%to 80.52%.Based on the modified EORTC criteria,two cases had complete response and nine cases showed partial response.The median longest diameter was 46.21(33.84,85.93)mm at baseline and 42.25(32.44,79.29)mm after medication,with a decrease ranging from 0.71%to 22.90%.Based on the modified RECIST 1.1 criteria,11 cases showed stable disease.Based on ICDS criteria,two cases had partial response and nine cases had stable disease.Conclusion PET/CT can be used to assess the efficacy of RANKL monoclonal antibody therapy for vertebral giant cell tumors,with a high objective response based on the modified EORTC criteria.
